Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Intellipharmaceutics Announces Second Quarter 2016 Results
http://www.intellipharmaceutics.com/releasedetail.cfm?ReleaseID=979321
I'm loving the pre-market ASK:
199.999,99 USD - http://de.advfn.com/borse/NASDAQ/IPCI/kurs
LOL!
Jonathan Aschoff from Brean Capital reiterated a Buy rating on IntelliPharmaCeutics Intl (NASDAQ: IPCI) with a price target of $8.
http://www.analystratings.com/2016/07/05/brean-capital-reiterates-a-buy-rating-on-intellipharmaceutics-intl/445587/
"IPCI (Intellipharmacuetics International) A pharmaceutics company with a wide pipeline of products including drug delivery systems and product candidates focused on Neurology, Diabetes, and pain. Having just closed their public offering this is a great time to buy with many short term catalysts. Price/Sales ratio is just right for IPCI, in line with their peers. Hovering around $3.00 last year and strong support under 1.50 means a short swing trade could be significant and low risk at these levels.
+Strong bounce from recent all time low
Buy under 1.50"
http://blog.objectiveforex.com/
Swiffer, thanks for the link: merz-dev.epoxyapp.com/login
But it was the same story with the german version of the EPOXY-Homepage. It was set up, to persuade the shareholders, that something is going on, but at the end it was a big fluff.
Bryon Franzen (?@bkfViking123) put $IPCI yesterday on his watchlist:
"$ipci watch list .... a stock of approvals on the fda's desk waiting for years" (https://twitter.com/bkfViking123)
For those, that follow ZACKS: They upgraded $IPCI to BUY
https://www.zacks.com/stock/quote/IPCI
"The stock of Intellipharmaceutics Internation (NASDAQ:IPCI) registered an increase of 12.61% in short interest. IPCI’s total short interest was 1.21 million shares in June as published by FINRA. Its up 12.61% from 1.07 million shares, reported previously. With 125,100 shares average volume, it will take short sellers 10 days to cover their IPCI’s short positions. The short interest to Intellipharmaceutics Internation’s float is 6.23%."
http://hintsnewsnetwork.com/intellipharmaceutics-internation-nasdaqipci-shorted-shares-increased-by-12-61/173147/
Thanks for all the interesting posts yesterday!
Doogdilinger, sorry for the following uninformed questions:
Your wrote:
"1st 2016 is the date AZ settled with all 6 co's coming to market with SeroquelXR" - could you please tell me the 6 companies, that will come to market, and whether any of them already have an FDA approval?
And your worte:
"In the case of SeroquelXR because AZ's patent protection expires this November we can actually track the timeline to FDA approval on this particular ANDA:)" - as I don't know how the FDA works: Do they need to give or deny the ANAD until the 1st of November?
Thanks
Sprot, i very much appreciate every contribution in the discussion about IPCI. But whether something is worth to consider or not, depends on the information given in the post. So when your write "There is an opportunity,but that will not before 2018 at least", then please give the reason that led you to your conclusion.
About Seroquel: Noone can know whether and if yes when any of the ANADs will get approval.
Vikinggames, the insiders are already heavily invested (and that is a very good sign):
Dr. Isa Odidi: 5,781,312
John N. Allport: 110,558
Domenic Della Penna: 173,700
Dr. Patrick Yat: 27,600
Dr. Eldon R. Smith: 21,731
Obviously there is a chance, that they buy more at the current SP. But noone can tell you, whether they will buy or not. It also does not really matter. The bigger question is, whether they will file Rexista in July/August, whether they find a partner and whether they get an approval for it or for one or more of their ANADs. You should be aware, that if something goes wrong with the tests for Rexista or non of the products will get approval, IPCI will end in insolvency. To invest in IPCI is speculating on a possible high reward, but doing so is also very risky and you can end up with empty hands.
Not about $IPCI, but interesting: FDA Advisors OK Abuse-Deterrent Opioid, Despite Concerns. Panel backs Vantrela but wants better outcome measures for product class
http://www.medpagetoday.com/Neurology/PainManagement/58373
Thanks for the answer and explanation
I found a long list with critical question about IPCI on the yahoo message board: http://finance.yahoo.com/mbview/threadview/;_ylt=Anu_sI1H67GO13q2.waQtNPeAohG;_ylu=X3oDMTB2YmE5ZG04BHBvcwMxMgRzZWMDTWVkaWFNc2dCb2FyZHNYSFJVbHQ-;_ylg=X3oDMTBhYWM1a2sxBGxhbmcDZW4tVVM-;_ylv=3?&bn=1f3c3552-08c0-338e-ba37-ae1dc549e9d6&tid=1465443288356-3feb654c-d830-4de3-81d1-991f41c04b91&tls=la%2Cd%2C0%2C3
On some of the question I would like to here, what the community here has to say:
"11) If they really file a NDA, will they have a chance in court against Purdue pharma?"
"13) Do you see any problems with a ph sensitive coating? If you don’t know what I am talking about read the PODRAS patent. Patent application title: COMPOSITIONS AND METHODS FOR REDUCING OVERDOSE Patent application number: 20160022590"
Thanks, doogdilinger. Leasing extra 40.000 square feet and rising the expenses from $90.000 to $240.000 is a very confident move. They are preparing for great success.
"For approximately ten years, we have occupied a 25,000 square foot facility at 30 Worcester Road, Toronto, Ontario, Canada M9W 5X2, that we leased in the year ended November 30, 2015 at a rental rate of approximately $90,000 per year, and with the Company responsible for utilities, municipal taxes and operating expenses for the leased property. On December 1, 2015, we entered into a new lease agreement for the combined properties comprising the Company’s premises that it currently operates from at 30 Worcester Road (“30 Worcester Road”, as well as a 40,000 square foot building on the adjoining property located at 22 Worcester Road, which is owned indirectly by the same landlord (“22 Worcester Road” and collectively with 22 Worcester Road, the “combined properties”) for a five-year term with a five-year renewal option. Basic rent over the five-year term is C$240,000 per annum, subject to an annual consumer price inflation adjustment, and the Company is responsible for utilities, municipal taxes and operating expenses for the leased property. With these two leased premises, we now have use of 65,000 square feet of commercial space to accommodate our growth objectives over the next several years. We also have an option to purchase the combined properties after March 1, 2017 and up to November 30, 2020 based on a fair value purchase formula. We use our facility at 30 Worcester Road as a research and development cGLP testing laboratory, office space, and cGMP scale-up and small to medium-scale manufacturing plant for solid oral dosage forms. The facility now consists of approximately 4,900 square ft. for administrative space, 4,300 square ft. for R&D, 9,200 square ft. for manufacturing, and 3,000 square ft. for warehousing. The 22 Worcester Road building provides approximately 37,000 square feet of warehouse space and approximately 3,000 square feet of office space. The current lease also provides the Company with a right of first refusal to purchase the combined properties. The landlord is required to provide the Company with prior written notice and the desired sale price for the combined premises prior to offering the premises to a third party or on the open market. The Company has five business days to accept such offer and purchase price for a transaction to close within 60 days of the notice. If the Company declines the offer, the landlord is entitled to offer and sell the properties for a purchase price of not less than the price offered to the Company for a period of 180 days, after which time the landlord is again obliged to offer the properties to the Company before offering them to a third party or on the open market.
Doogdilinger, I have a short question (I am still reading through all the available informations - but unfortunatly, I don't have much time). You wrote in one of your posts:
"What we do know is that they saw fit to lease more space for some reason."
In the NEWS from May 2015 it says:
"today announced that it has agreed to purchase the land and building from which it conducts its operations at 30 Worcester Road, Toronto, Ontario (the "operating property") as well as the land and building of the adjoining property at 22 Worcester Road (the "adjoining property") for a combined purchase price of Cdn. $4,700,000. The operating property has been occupied by the Company since 2004 pursuant to a lease, and is approximately 25,000 sq. ft. The adjoining property includes a building of approximately 40,000 sq. ft. that is not currently occupied by the Company. The adjoining property is expected to provide the Company with space that will permit expansion of the Company's operations. There can be no assurance that the purchase transaction will be completed."
I could not find any proof, that the transaction was completed. Did they at the end also bought the adjoining property?
I hope that IPCI finds quick a partner for Keppra:
Jubilant Life surges 6% on USFDA approval for epilepsy injection "We have received abbreviated new drug application (ANDA) final approval for Levetiracetam injection USP, 500 mg/5 ml (100 mg/ml), the generic version of Keppra injection of UCB," an integrated global pharmaceuticals and life sciences company said in its filing.
Read more at: http://www.moneycontrol.com/news/buzzing-stocks/jubilant-life-surges-6usfda-approval-for-epilepsy-injection_6815741.html?utm_source=ref_article
I just read about this stock in a forum about another company (PTK).
Nice to see the continuous automated buying of 100 shares. Someone is accumulating.
Okay, found your source. Sorry, did not read the NEWS about the 2ß15 year end results:
"In February 2015, we announced that we had entered into an agreement with Teva Pharmaceuticals USA, Inc. (“Teva”) by which we had granted Teva an exclusive license to market in the United States an extended release drug product candidate for which we have an ANDA pending FDA approval. The agreement contemplated the FDA granting regulatory approval by a date certain, which did not occur, and the agreement has been terminated subsequent to year-end. The Company is in discussions with Teva concerning an alternate product candidate. There can, however, be no assurance that an acceptable alternate product candidate, or any terms relating thereto, will be agreed upon."
https://globenewswire.com/news-release/2016/02/27/814830/0/en/Intellipharmaceutics-Announces-2015-Year-End-Results.html
Where do you read, that the deal expired?
"2nd ANDA partnered with TEVA awaiting FDA approval(Speculation is that this is a partnership deal on Seroquel)"
Why should it be Seroquel and not another ANAD?
About the MetroPCs-Partnership: In the NEWS was stated, that the partnering with 9 MetroPCS authorized dealers and 55 locations in New York will lead to the launch of a white label version in May - respectively the launch in May was targeted. But until today, nothing seemed to happen. I would guess, that we could read somewhere in the internet at least about the launch. But I couldn't find anything: no advertisement for the app, no mention of Welcome Day events etc. That reminds me very much about EPOXY's statement about beta-testing in Germany, that was nothing but full of hot air.
Thanks for the information.
Question:
I am collecting informations about the company, and would appreciate your help. On their homepage it is written about their ANDA strategy: "For existing controlled-release (once-a-day) products covered by patents about to expire or already expired, we can formulate generic products, which are bioequivalent to the branded products. Such products can be licensed to and sold by distributors of generic products. Our scientists have previously demonstrated a successful track record with such products, having developed several drugs on a private contract basis. The regulatory pathway for this approach requires an abbreviated new drug application ("ANDA")."
I would like to know which drugs were developed on a private contract basis. Anyone knows?
"IPCI (MC $44 M) 8 Drugs awaiting FDA approval =1000%+ Potential !!!
IPCI has a very large and attractive Product Pipeline with 8 Drugs awaiting FDA approval which could they could approved anytime now . Their Key Drug is Rexista a potential Best in Class Abuse Deterrent Pain Drug with HUGE Market Potential . NDA Filing for the Drug is planned within Weeks (June or July) .We could see $5++ easily with NDA filing and Runup to FDA decision (4Q16 or early 1Q2017) and much higher if there is any approval of the Drugs under review by FDA . This ultra Low float Stock is a lifetime opportunity here close at ATL . GL"
See more at: http://www.stockstobuy.org/forum/topics/ipci-mc-44-m-8-drugs-awaiting-fda-approval-1000-potential
How POET Technologies (V.PTK) is disrupting the opto-electronics industry
Read more at http://www.stockhouse.com/news/newswire/2016/01/20/how-poet-technologies-v-ptk-disrupting-opto-electronics-industry#WP0TG9sY3IjQuIRg.99
With some great statements from the CEO.
Swiffer, can you please give a link?
BlackBeerd, what do you think about the Q2-numbers?
$EPXY in fact awaits the approval for their new App Version and will start soon a marketing roll-out. So, there is a good chance for a big rebound.
$EPXY has a huge spread, look at yesterday's chart and also the long slide down (half a year chart). Looks like there will be a upswing. What do you think?
NT 10-Q
http://yahoo.brand.edgar-online.com/displayfilinginfo.aspx?FilingID=10867848-1139-11314&type=sect&TabIndex=2&companyid=773044&ppu=%252fdefault.aspx%253fcik%253d1428816
The Company expects to report a net operating loss of approximately $247,822 for the six months ended June 30, 2015, as compared to a net operating loss of $75,953 in the same period ended June 30, 2014; and to report a net loss of approximately $122,776 for the six months ended June 30, 2015, as compared to a net loss of $116,787 in the prior comparative period. The substantive increase to operating costs is predominantly the result of increased general and administrative expense from $83,687 in the six months ended June 30, 2014 to $257,806 in the six months ended June 30, 2015 as a result of increased expenditure on advertising and marketing, consulting fees, management salaries and listing and filing expenses.
Other expenses during the six months ended June 30, 2015 include a gain on the change of the fair value of derivative liabilities of $444,235 compared to a loss of $16,727 in the prior period, and interest expenses of $319,189 (2015) as compared to only $24,107 as at June 30, 2014.
Revenue increased period over period from $7,734 to $15,645 in the six months ended June 30, 2015.
Any thoughts, why it takes so long for EPOXY to get the approval from Apple? I know, they wrote in the NEWS, that it may take "few weeks", but if you check, the "Average App Store Review Time" is just 6 days: http://appreviewtimes.com/
Also, in first place, it seemed weird, that they published the NEWS about the new version even befor getting the approval for the App Store by Apple.
The link in my earlier post did not work. Here is the right one: http://www.cspnet.com/category-news/services/articles/speedee-mart-adding-loyalty-program-0
http://www.cspnet.com/category-news/services/...ing-loyalty-program-0
"Speedee Mart Adding Loyalty Program
Rolling out Epoxy’s smartphone-based rewards app at all 20 c-stores in Las Vegas area
Published in CSP Daily News
HENDERSON, Nev. -- On August 1, Speedee Mart launched a mobile app through Epoxy Inc. in all 20 of its Las Vegas-area convenience stores, spanning Henderson, Las Vegas and North Las Vegas.
Speedee Mart will be using the rewards program component of the Epoxy app in full capacity. The company plans to provide special offers on products like milk and services like carwashes.
The chain does not have a formal website, a spokesperson for Epoxy told CSP Daily News. The Epoxy program is app based, accessed through smartphones, and it does not depend on a website.
"We are excited to have Speedee Mart join the growing list of stores, continuing the expansion of the Epoxy Family," said Dave Gasparine, Epoxy founder and CEO. "Bigger companies are starting to understand the value Epoxy brings to the table and that is an extremely powerful achievement for the app as we aim to garner the interest of larger chains."
Epoxy is the developer of the Epoxy App for iPhone iOS and Android operating systems. It is a smartphone application designed to connect business owners and consumers in order to ease marketing frustrations. The mobile app gives loyal customers the ability to keep track of virtual loyalty cards and mobile gift cards all in one place while also giving opportunities to review and share businesses with friends. In turn, Epoxy provides businesses the ability to reward customers, share offers and deliver information about special events right to their smartphones.
Epoxy also recently announced it will be releasing a new and improved app design within the next few weeks.
Speedee Mart, also is a family-owned and -operated c-store chain managed by Wally Emery, CEO. Most of its stores include carwashes and all of the locations have gaming. Speedee Mart also has exclusive rights across the Las Vegas valley for a pay system called PaySite, the only chain in southern Nevada to offer these convenient bill payment kiosks."
Gas Station ?@gas_station 5. Aug.
Speedee Mart Adding Loyalty Program: On August 1, Speedee Mart launched a mobile app through Epoxy Inc. in all... http://bit.ly/1T3DkaW
@Blackbeerd, thanks for your answer. Let's hope, that EPOXY is working on it!
Interesting! I think marketing is starting ...
https://twitter.com/JimmyJMMA/status/627591023204503552/photo/1
Epoxy is an official sponsor of Jimmy Jones
?
Black Beerd, as you wrote, the NEWS comprises a nice measurement for success. Let's hope, as it is stated in the NEWS, that EPOXY manages to run with the momentum. Maybe the testimonial from Speedee will make Kwik Trip reconsider EPOXY. What do you think? Did you hear again anything?